undamentalytics Newsletter
Sign in

Volitionrx LTD income statement

In fiscal 2025, Volitionrx LTD reported revenue of $1.7m, up 40.0% on the year before, operating income of −$21.7m (a -1258.5% margin) and net income of −$23.4m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122014Dec 20142019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue00000001122
Research and development234101513152014109
Selling and marketing———11477543
General and administrative00056121010899
Operating income−3−4−6−16−21−28−32−36−27−22−19
Interest expense———000—————
Net income−3−4−8−16−20−27−31−36−27−23−26
Diluted EPS−$0.15−$0.15−$0.20−$0.41−$0.45−$0.51—−$0.50−$0.31——
Diluted shares (average)—28m40m39m45m53m—71m87m107m—
EBITDA−2−4−6−15−21−27−31−35−26−21−19

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: FEMY vs VNRXICCM vs VNRXICU vs VNRX

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Volitionrx LTD's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Volitionrx LTD.